I believe we are waiting for some new evidence that
I believe we are waiting for some new evidence that supports all the previous peace meal data, that can clearly stand on it's own.
Good progress takes time and usually takes making changes as we move forward, which we have clearly seen with Leronlimab. The end is near for sure. We are close to proving we can treat our indication.
We now have the indication, but we still need to prove it, which could be as early as 6 months or maybe a year at most (for initial large scale data review).
Maybe we will get a partial commitment from someone between then and now, but it would only happen if we need the funds to continue going forward. I just don't think management is ready to give any future profit margin to anyone just yet in return for funding to keep us going. That would not be in our best interest and would only result in a small rise in share price.
I don't think any partner will commit large sums of capital until they feel highly certain that they would get an FDA approval and that there is a market for the indication that we are advertising.
Lots of things simmering for sure and I think we should be hearing about forward progress on several of those items soon. I'm happy to just not have negative news about something we are doing.
There is way too much evil in the BIO-Pharma Industry (evil empire) and I'm sick and tired of seeing us be the victims, and yes, I do believe somebody pulled some strings to get us put on a hold. So don't let anyone know we have the achieved the success we need until we actually achieve it.
Until we have irrefutable evidence that meets the basic minimum industry/FDA standard, we should not be giving shorts, day-traders, and the evil empire any news that can be used to cause us harm.
I'll just buy more if CYDY goes on sale. I've already increased my initial investment by 20x so lets do 40x (lol). I can wait 12 more months or longer if necessary. If you're staring at the share price all the time, you might as well keep buying. At least you'll get a little bit more satisfaction. At least I do.
16
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Biotech Investment: Between a Rock and a Hard Place The U.S. Department of the Treasury just threw a curveball at the biotechnology sector with its proposal to shore up the Comprehensive Outbound Investment National Security (COINS) Act. This ain't just another set of lines on a folded napkin; the new rules would put a chokehold on American investments flowing into...
Continue Reading
Grappling with Medicare's Gaps Most folks hear Medicare and feel a sigh of relief—thinking it's a catch-all net for healthcare in your golden years. But hold on, when it comes to long-term care, Medicare's got more holes than Swiss cheese. Cindy Couyoumjian from Cinergy Financial lays it out pretty clear: Medicare doesn't cover what it calls 'custodial care'—you know,...
Continue Reading
Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...
Continue Reading
Unexpected Surge in Northern Virginia's Inventory Walking around Fairfax these days, you might feel like you're in a time warp, especially if you're tracking the housing market. See, while the rest of the country's housing market groans under sluggish sales and creeping prices, Northern Virginia's doing a dance of its own. Inventory's ballooning faster than a parade...
Continue Reading
Punching Through to New Opportunities Folks, here's one for the record books: the Team Boxing League (TBL) just nabbed the promoter license from the New York State Athletic Commission, or NYSAC if you're into the alphabet soup. This isn't just paperwork getting shuffled around an office; it's a massive leap forward for team boxing, a sport that steps into the heart of New...
Continue Reading
The Grind of Securing a Limited-Edition Supercar If you're grinding to buy one of those elusive limited-edition supercars, you'd better buckle up. According to Kendall Gath over at iLusso, this ain't like picking up groceries at the local market. There's a whole list of things to consider before you even think about handing over your wad of cash. Differentiating Fact from...
Continue Reading
Volvo Group's Robust Q3 Performance It's not every day that you see a company like Volvo Group churning out results that make you take a second sip of that morning coffee. But here we are—looking at Q3 2026 with growth numbers that pack a punch. You can't argue with SEK 119.5 billion in net sales, especially when organic sales growth hit 7%. That's no small feat in...
Continue Reading
The Fusion of Italian Artistry and Innovation Imagine blending business savvy with a touch of culture and ethics. That's the spirit of the 9th Business Care International Award, which is gearing up to hit New York City's grand stage come November 18-19. This ain't just about pats on the back; it's a recognition of those who push Italian excellence across oceans and into...
Continue Reading
Diving Into Hyperliquid's $100 Million Bold Move Let’s cut through the corporate fluff—Hyperliquid Strategies Inc. just cranked up their stock repurchase program to a cool $100 million. Yep, that’s right—the brain trust behind NASDAQ:PURR has pulled out the checkbook to buy more of its own shares. This decision, unveiled on October 23, 2026, is like tossing a...
Continue Reading
Stock Hit and Legal Drama Panic set in when Better Home & Finance Holding Company took a 28.5% nosedive after spilling some less-than-sweet news. Their promise of hitting a billion in monthly loans? Stuck in limbo as borrower trepidation reared its ugly head amidst rising rates. Investors felt the heat, watching shares skydive $12.17, landing them at a bruised $30.52. A...
Continue Reading
Top 5 Most Recently Viewed Articles
Analyzing Short Interest Trends for Lennar Corporation Lennar Corporation (NYSE: LEN) has recently experienced a significant decline in its short percent of float, which has fallen by 11.2% since the last report. Currently, the company has reported a total of 4.67 million shares sold short, representing approximately 2.22% of the total regular shares available for...
Continue Reading
Recognition for BELFOR Franchise Group Brands Five esteemed brands from BELFOR Franchise Group have been acknowledged in the Entrepreneur Franchise 500 list, showcasing their outstanding status in the franchising sector. The brands that have made the list include The Patch Boys, Blue Kangaroo Packoutz, redbox+ Dumpsters, Chem-Dry, and 1-800 WATER DAMAGE. This recognition...
Continue Reading
Gas Insulated Switchgear Market Growth and Innovations The global gas insulated switchgear market is experiencing a remarkable evolution, showcasing an impressive growth trajectory. Recent evaluations reflect a valuation of approximately US$ 28.02 billion and forecasted to reach US$ 55.55 billion within a few years. This represents a promising compound annual growth rate...
Continue Reading
NPS Supports Korea Zinc's Management Amidst Industry Concerns The National Pension Service (NPS), recognized as the world's third-largest pension fund, has taken a pivotal stand by announcing its voting direction for Korea Zinc's upcoming Extraordinary General Meeting (EGM). This decision is expected to have significant repercussions for the company and the broader...
Continue Reading
Market Analysts Share Insights on Trump's Inauguration Speech Donald Trump’s inauguration as the 47th President of the United States stirred an insightful variety of responses from Wall Street analysts. With a clear focus on trade, tariffs, and the overall direction of policy, analysts delved into the implications of his speech on the economy. Reactions from Financial...
Continue Reading